Drug Trial Radar · NCT00174993
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Feb 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,373
Actual
Start
May 2001
Primary completion
Jan 2005
Study completion Jan 2005
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes.
Conditions
- Diabetes Mellitus
Interventions
PioglitazoneDrug
Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
PlaceboDrug
Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to the Composite of All Cause Mortality, Non-Fatal Myocardial Infarction, Stroke, Acute Coronary Syndrome, Major Leg Amputation, Cardiac Intervention, Bypass Surgery or Leg Revascularization.Time frame: At First Occurrence
Locations
19 sites in 19 countries. Site status is shown where the registry gives one.
Site not named
Multiple Cities, Austria
Site not named
Multiple Cities, Belgium
Site not named
Multiple Cities, Czechia
Site not named
Multiple Cities, Denmark
Site not named
Multiple Cities, Estonia
Site not named
Multiple Cities, Finland
Site not named
Multiple Cities, France
Site not named
Multiple Cities, Germany
Site not named
Multiple Cities, Hungary
Site not named
Multiple Cities, Italy
Site not named
Multiple Cities, Latvia
Site not named
Multiple Cities, Lithuania
Site not named
Multiple Cities, Netherlands
Site not named
Multiple Cities, Norway
Site not named
Multiple Cities, Poland
Site not named
Multiple Cities, Slovakia
Site not named
Multiple Cities, Sweden
Site not named
Multiple Cities, Switzerland
Site not named
Multiple Cities, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.